ASX Linkedin Twitter               

 

Scientific Publications

Kathryn A Skelding, Richard D Barry, Darren R Shafren (2012) Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride. Invest New Drugs
Gough G Au, Leone G Beagley, Erin S Haley, Richard D Barry, Darren R Shafren (2011) Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18. Virol J, 8:22
Erin S Haley, Gough G Au, Brian R Carlton et al. (2009) Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer. J Mol Med 87: 385-399
Linda J Berry, Gough G Au, Richard D Barry et al. (2008) Potent oncolytic activity of human enteroviruses against human prostate cancer. The Prostate 68: 577-87
Kathryn A. Skelding, Richard D. Barry, Darren R. Shafren (2009) Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. Breast Cancer Res Treat. 113: 21-30.
Gough G. Au, Lisa F. Lincz, Arno Enno, Darren R. Shafren (2007) Oncolytic Coxsackievirus A21 as a novel therapy for multiple myleoma. Br J Haematol. 137: 133-141.
Gough G. Au, A. Michael Lindberg, Richard D. Barry, Darren R. Shafren (2005) Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol. 26: 1471-1476
Darren R. Shafren, Dianne Sylvester, E. Susanne Johansson, Ian G. Campbell, Richard D. Barry (2005) Oncolysis of human ovarian cancers by echovirus type 1. Int J Cancer, 115: 320-328
E. Susanne Johansson, Li Xing, R. Holland Cheng, Darren R. Shafren (2004) Enhanced cellular receptor usage by a bioselected variant of Coxsackievirus A21. J Virol 78: 12603-12612
Nicole G. Newcombe, Leone G. Beagley, Dale Christiansen, Bruce E. Loveland, E. Susanne Johansson, Ken W. Beagley, Richard D. Barry, Darren R. Shafren (2004) Novel role for decay-accelerating factor in Coxsackievirus A21-mediated cell infectivity. J Virol. 78: 12677-12682
Nicole G. Newcombe, E. Susanne Johansson, Gough Au, A. Michael Lindberg, Richard D. Barry, Darren R. Shafren (2004) Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection. J Virol. 78: 1431-1439.
Darren R. Shafren, Gough G. Au, Tam Nguyen, Nicole G. Newcombe, Erin S. Haley, Leone Beagley, E. Susanne Johansson, Peter Hersey, Richard D. Barry (2004) Systemic therapy of malignant human melanoma tumors by a common cold-producing virus, Coxsackievirus A21. Clin Cancer Res, 10: 53-60.
Nicole G. Newcombe, Per Andersson, E. Susanne Johansson, Gough G. Au, A. Michael Lindberg, Richard D. Barry, Darren R. Shafren (2003) Cellular receptor interactions of C-cluster human group A coxsackieviruses. J Gen Virol. 84: 3041-3050.
Darren R. Shafren, Douglas J. Dorahy, Rick F. Thorne, Richard D. Barry (2000) Cytoplasmic interactions between decay-accelerating factor and intercellular adhesion molecule-1 are not required for coxsackievirus A21 infection. J Gen Virol. 81: 889-894.
D. R. Shafren, J. Gardner, V. H. Mann, T. M. Antalis, A. Suhrbier (1999) Picornavirus receptor down-regulation by plasminogen activator inhibitor type 2. J Virol. 73: 7193-7198.
Darren R. Shafren (1998) Viral cell entry induced by cross-linked decay-accelerating factor. J Virol. 72: 9407-9412.
Darren R. Shafren, Douglas J. Dorahy, Rick F. Thorne, Taroh Kinoshita, Richard D. Barry, Gordon F. Burns (1998) Antibody binding to individual short consensus repeats of decay-accelerating factor enhances enterovirus cell attachment and infectivity. J Immunol. 160: 2318-2323.
Darren R. Shafren, David T. Williams, Richard D. Barry (1997) A decay-accelerating factor-binding strain of Coxsackievirus B3 requires the Coxsackievirus-Adenovirus receptor protein to mediate lytic infection of Rhabdomyosarcoma cells. J Virol. 71: 9844-9848.
Michael V. Agrez, Darren R. Shafren, Xinhua Gu, Karen Cox, Dean Sheppard, Richard D. Barry (1997) Integrin αVβ6 enhances Coxsackievirus B1 lytic infection of human colon cancer cells. Virol. 239: 71-77.
Darren R. Shafren, Douglas J. Dorahy, Rebecca A. Ingham, Gordon F. Burns, Richard D. Barry (1997) Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule-1 for cell entry. J Virol. 71: 4736-4743.
Darren R. Shafren, Douglas J. Dorahy, Sandra J. Greive, Gordon F. Burns, Richard D. Barry (1997) Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by Coxsackievirus A21. J Virol. 71: 785-789.
Darren R. Shafren, Richard C. Bates, Michael V. Agrez, Robert L. Herd, Gordon F. Burns, Richard D. Barry (1995) Coxsackieviruses B1, B3, and B5 use decay-accelerating factor as a receptor for cell attachment. J Virol. 69: 3873-3877.
Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).